Management of urothelial carcinoma / Ja Hyeon Ku, editor.
This book provides a comprehensive overview of contemporary evidence-based management of urothelial carcinoma. The first part of the book is devoted to urothelial carcinoma of the bladder and includes detailed description of the diagnosis and treatment of non-muscle-invasive, muscle-invasive, and ad...
Saved in:
| Online Access: |
Full Text (via Springer) |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Singapore :
Springer,
2019.
|
| Subjects: |
MARC
| LEADER | 00000cam a2200000xi 4500 | ||
|---|---|---|---|
| 001 | b10451520 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 190121s2019 si a o 001 0 eng d | ||
| 005 | 20240423172448.0 | ||
| 019 | |a 1082452561 |a 1083040321 |a 1086463707 |a 1089999063 | ||
| 020 | |a 9789811055027 |q (electronic bk.) | ||
| 020 | |a 9811055025 |q (electronic bk.) | ||
| 020 | |z 9789811055010 |q (print) | ||
| 020 | |a 9811055017 | ||
| 020 | |a 9789811055010 | ||
| 024 | 7 | |a 10.1007/978-981-10-5502-7 | |
| 035 | |a (OCoLC)spr1083095979 | ||
| 035 | |a (OCoLC)1083095979 |z (OCoLC)1082452561 |z (OCoLC)1083040321 |z (OCoLC)1086463707 |z (OCoLC)1089999063 | ||
| 037 | |a spr978-981-10-5502-7 | ||
| 040 | |a GW5XE |b eng |e rda |e pn |c GW5XE |d OCLCF |d UAB |d EBLCP |d VT2 |d LEAUB |d YDX |d DKU | ||
| 049 | |a GWRE | ||
| 050 | 4 | |a RC280.B5 | |
| 245 | 0 | 0 | |a Management of urothelial carcinoma / |c Ja Hyeon Ku, editor. |
| 264 | 1 | |a Singapore : |b Springer, |c 2019. | |
| 300 | |a 1 online resource (vi, 196 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent. | ||
| 337 | |a computer |b c |2 rdamedia. | ||
| 338 | |a online resource |b cr |2 rdacarrier. | ||
| 347 | |a text file |b PDF |2 rda. | ||
| 500 | |a Includes index. | ||
| 505 | 0 | |a Intro; Contents; Part I: Non-muscle Invasive Bladder Cancer; 1: Epidemiology, Etiology, and Histopathology; 1.1 Epidemiology; 1.2 Etiology; 1.2.1 Genetic Factors; 1.2.2 Environmental Factors; References; 2: Histopathology; 2.1 Urothelial Carcinoma; 2.1.1 Carcinoma In Situ; 2.1.2 Lymphovascular Invasion; 2.1.3 Histologic Variant of Urothelial Carcinoma; 2.1.4 T1 Sub-staging; References; 3: Symptoms and Work-Up; 3.1 Hematuria; 3.1.1 Diagnostic Value of Hematuria; 3.1.2 Gender Difference and Hematuria (SEER DB); 3.1.3 Asymptomatic Microscopic Hematuria. | |
| 505 | 8 | |a 3.2 Lower Urinary Tract Symptoms3.3 Modalities for Upper Tract Evaluation; References; 4: Cystoscopy; 4.1 Indication; 4.2 Instrument; 4.3 Procedure; 4.3.1 Preparation; 4.3.2 Anesthesia; 4.3.3 Recommendation for Prophylactic Antibiotics; 4.3.4 Bladder Inspection; 4.4 Typical Findings of Bladder Cancer; 4.5 Benefits for Using Flexible Cystoscopy in Male Patient; 4.6 Advance Cystoscopy Technique (NBI/PDD/OCT); 4.6.1 Narrowband Imaging (NBI); 4.6.2 Photodynamic Diagnosis; 4.6.3 Microscopic Imaging; 4.6.4 Other Upcoming Imaging Technologies; 4.7 Follow-Up; References. | |
| 505 | 8 | |a 5: Urine Cytology and Emerging Biomarkers5.1 Urine Cytology; 5.1.1 Normal Findings in Cytology; 5.1.2 Malignant Findings in Cytology; 5.1.3 Routine Evaluation of Urine Cytology in Hematuria Patients; 5.1.4 Washing Cytology vs. Voided Urine Cytology; 5.1.5 The Paris System for Reporting Urinary Cytology (PSRUC); 5.1.5.1 Pros and Cons of the Paris System for Reporting Urinary Cytology; 5.2 Biomarker; 5.2.1 Currently Available Biomarkers; 5.2.2 Urinary Biomarker; 5.2.2.1 Nuclear Matrix Protein-22 (NMP22); 5.2.2.2 Bladder Tumor Antigen (BTA); 5.2.2.3 Urine Protein. | |
| 505 | 8 | |a 5.2.2.4 Urine MicroRNA5.2.3 Cell-Based Biomarker; 5.2.3.1 ImmunoCyt/uCyt; 5.2.3.2 Fluorescence In Situ (FISH) Test; References; 6: Modifiable Risk Factor to Prevention; 6.1 Smoking Cessation; 6.2 Avoid Occupational Carcinogen Exposure; 6.3 Other Modifiable Factors; References; 7: Transurethral Resection of Bladder Tumor; 7.1 Instrument; 7.2 Procedure; 7.2.1 Preparation; 7.2.2 Tumor Resection; 7.3 Complication; 7.4 Monopolar/Bipolar TURBT; 7.5 Repeated TURBT; 7.6 Transurethral Prostate Biopsy; 7.7 Bladder Random Biopsy (Mapping Biopsy); 7.8 Routine Biopsy after BCG. | |
| 505 | 8 | |a 7.9 En Bloc Resection of Bladder TumorReferences; 8: Intravesical Instillation Therapy; 8.1 Immediate Post-TURBT Intravesical Chemotherapy; 8.1.1 Efficacy; 8.1.2 Protocol; 8.2 Induction and Maintenance Intravesical Chemotherapy; 8.2.1 Chemotherapeutic Agents; 8.2.2 Protocol; 8.2.3 Optimization; 8.3 Intravesical BCG Immunotherapy; 8.3.1 Introduction; 8.3.2 BCG Strain; 8.3.3 Protocol; 8.3.4 Adverse Effects; 8.3.5 BCG-Unresponsive NMIBC; 8.3.6 BCG Shortages; 8.4 New Definition of Disease Progression; References; 9: Early Radical Cystectomy. | |
| 520 | |a This book provides a comprehensive overview of contemporary evidence-based management of urothelial carcinoma. The first part of the book is devoted to urothelial carcinoma of the bladder and includes detailed description of the diagnosis and treatment of non-muscle-invasive, muscle-invasive, and advanced or metastatic disease. Attention then turns to upper tract urothelial carcinoma (UTUC), with individual chapters on diagnosis, nephron-sparing surgery, nephroureterectomy, and treatment of advanced or metastatic UTUC. The text is supported by many illustrations, photos, and tables that clarify management, and surgical video clips are also available to readers. The book will be a welcome addition to the literature as progress continues to be made in understanding the exact pathophysiology of urothelial carcinoma and in developing more effective diagnostic and therapeutic modalities. It will be useful both to researchers in the field of urothelial carcinoma and to clinicians, including especially residents and fellows. | ||
| 588 | 0 | |a Online resource; title from PDF title page (SpringerLink, viewed January 21, 2019) | |
| 650 | 0 | |a Bladder |x Cancer |x Treatment. |0 http://id.loc.gov/authorities/subjects/sh2010008289. | |
| 650 | 7 | |a Bladder |x Cancer |x Treatment. |2 fast |0 (OCoLC)fst00834069. | |
| 700 | 1 | |a Ku, Ja Hyeon, |e editor. |0 http://id.loc.gov/authorities/names/n2018042450. | |
| 776 | 0 | 8 | |i Print version: |a Ku, Ja Hyeon |t Management of Urothelial Carcinoma |d Singapore : Springer,c2019 |z 9789811055010. |
| 856 | 4 | 0 | |u https://colorado.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-981-10-5502-7 |z Full Text (via Springer) |
| 907 | |a .b10451520x |b 03-19-20 |c 04-16-19 | ||
| 998 | |a web |b 04-30-19 |c b |d b |e - |f eng |g si |h 0 |i 1 | ||
| 907 | |a .b10451520x |b 07-02-19 |c 04-16-19 | ||
| 944 | |a MARS - RDA ENRICHED | ||
| 907 | |a .b10451520x |b 04-30-19 |c 04-16-19 | ||
| 915 | |a I | ||
| 956 | |a Springer e-books | ||
| 956 | |b Springer Nature - Springer Medicine eBooks 2019 English International | ||
| 999 | f | f | |i ae0602e9-fa70-5bca-a750-e7f767dba03b |s 261cc09c-f9c7-54a9-8438-1303493573c8 |
| 952 | f | f | |p Can circulate |a University of Colorado Boulder |b Online |c Online |d Online |e RC280.B5 |h Library of Congress classification |i Ebooks, Prospector |n 1 |